title: Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients.
abstract: Hepcidin is a key regulator of iron metabolism. In this study, we examined whether measurement of hepcidin is useful in assessing recombinant human erythropoietin (rHuEPO) responsiveness in regular hemodialysis (HD) patients in a cross-sectional fashion. We examined the association between serum prohepcidin, a prohormone of hepcidin, and rHuEPO dosage and the rHuEPO/hemoglobin (Hb) ratio in 75 HD patients. We also semiquantatively measured the peak intensity of serum hepcidin-25, the major form of mature hepcidin, in 24 HD patients by using surface-enhanced laser desorption ionization time of flight time mass spectrometry, and compared those between rHuEPO-hyporesponsive (rHuEPO 192 +/- 10 [126-252] IU/kg/week, n = 15) and responsive patients (rHuEPO 40 +/- 9 [0-81] U/kg/week, n = 9). A significant but weak relationship was found between serum prohepcidin and rHuEPO dosage (r = 0.24, p < 0.05) and rHuEPO/Hb ratio (r = 0.22, p = 0.06). However, prohepcidin did not become an indicator of hematopoietic parameters by multiple regression analysis. Serum hepcidin-25 intensity was significantly and positively correlated with ferritin (r = 0.51, p < 0.01) but not with log-transformed C-reactive protein. There was no difference in the intensities of serum hepcidin-25 between rHuEPO-hyporesponsive and responsive patients (64 +/- 10 vs. 52 +/- 16 AU, p = NS). It follows from these findings that the assessment of serum hepcidin using currently available assays was not valid in predicting rHuEPO responsiveness in chronic HD patients.
authors.affiliation: Division of Blood Purification, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan. a.kato@hama-med.ac.jp
authors.forename: Akihiko
authors.initials: A
authors.lastname: Kato
authors.forename: Takayuki
authors.initials: T
authors.lastname: Tsuji
authors.forename: Jinghui
authors.initials: J
authors.lastname: Luo
authors.forename: Yukitoshi
authors.initials: Y
authors.lastname: Sakao
authors.forename: Hideo
authors.initials: H
authors.lastname: Yasuda
authors.forename: Akira
authors.initials: A
authors.lastname: Hishida
mesh_terms: D000368:Aged; D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D023181:Antimicrobial Cationic Peptides / Q000097:blood*; D015415:Biomarkers / Q000097:blood*; D003430:Cross-Sectional Studies; D016903:Drug Monitoring / Q000379:methods / Q000592:standards*; D004921:Erythropoietin / Q000008:administration & dosage*; D005260:Female; D005293:Ferritins / Q000097:blood*; D064451:Hepcidins; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications / Q000628:therapy; D008297:Male; D011498:Protein Precursors / Q000097:blood*; D011994:Recombinant Proteins; D006435:Renal Dialysis; D015203:Reproducibility of Results
chemical_list: D023181:Antimicrobial Cationic Peptides; D015415:Biomarkers; C578702:HAMP protein, human; D064451:Hepcidins; D011498:Protein Precursors; D011994:Recombinant Proteins; D004921:Erythropoietin; D005293:Ferritins